Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit"

BMJ (Clinical research ed.)

Volumn 357, Issue , 2017, Pages j2097-

  Cohen, Deborah ^a  

^a British Medical Journal Technology Assessment Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVISORY COMMITTEE; COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; ECONOMICS; GOVERNMENT; HUMAN; NATIONAL HEALTH SERVICE; SUPPLY AND DISTRIBUTION; UNITED KINGDOM;

ADVISORY COMMITTEES; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG INDUSTRY; GOVERNMENT AGENCIES; HUMANS; STATE MEDICINE; UNITED KINGDOM;

EID: 85019741192     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2097     Document Type: Note

References (0)